Imagine being told you have cancer that has spread beyond your prostate. For thousands of men each year, that news is devastating. But a new long-term analysis offers real hope.
A drug called enzalutamide (brand name Xtandi) is already used for advanced prostate cancer. Now we know just how much it can help over five years. The results are striking.
Prostate cancer is the second most common cancer in men worldwide. When it spreads to other parts of the body, doctors call it metastatic hormone-sensitive prostate cancer (mHSPC).
Standard treatment has been hormone therapy that lowers testosterone. This works for a while. But the cancer often learns to grow despite low testosterone levels.
That is where enzalutamide comes in. It blocks the signals that tell prostate cancer cells to grow. Think of it like a key that no longer fits the lock. The cancer cells cannot get the "grow" signal anymore.
The ARCHES trial started in 2016. It included 1,150 men with metastatic prostate cancer. Half received enzalutamide plus standard hormone therapy. The other half received a placebo plus standard therapy.
After more than five years of follow-up, the difference was clear.
Men who took enzalutamide had a 66 percent chance of surviving five years. In the placebo group, that number was 53 percent. That is a 13 percentage point difference.
This means one in every eight men lived who might not have otherwise.
For men with high-volume disease (cancer that has spread extensively), the benefit was even larger. They lived about three years longer on average.
But There's a Catch
The results come from a "post hoc" analysis. That is a fancy way of saying researchers looked back at the data after the main study was done. This type of analysis is less reliable than a planned study.
The researchers are honest about this. They say the survival numbers should be interpreted carefully. Still, the pattern is strong and consistent across different groups of men.
What Changed After Five Years
No new safety problems appeared. The side effects were similar to what doctors already know about enzalutamide. These can include fatigue, hot flashes, and high blood pressure.
The study also showed that most men in the enzalutamide group chose to keep taking the drug after the main study ended. About 65 percent continued in the open-label extension. Only 32 percent of the placebo group did the same.
This tells us that men and their doctors felt the benefits were worth continuing.
If you or a loved one has metastatic prostate cancer, this information matters. Enzalutamide is already approved by the FDA. It is available now.
Talk to your oncologist about whether adding enzalutamide to standard hormone therapy makes sense for your specific situation. The drug works best when started early in the treatment journey.
Not every man will benefit the same way. Your cancer's characteristics, your overall health, and other factors all play a role.
The Limits of This Study
This was not a fresh trial. It was a look back at older data. The original study was "unblinded" in 2018, meaning everyone learned who got the real drug. After that, some men switched treatments. This can muddy the results.
Also, the survival benefit was calculated using statistical methods that are less strict than the main study rules. The researchers call the p-value "nominal," which means it should not be taken as final proof.
What Happens Next
The ARCHES trial is now complete. But the story does not end here. Researchers will continue to track these men to see how long the benefits last.
Other studies are testing enzalutamide in earlier stages of prostate cancer. The goal is to catch the disease before it spreads. That could save even more lives.
For now, this five-year data gives doctors and patients a clearer picture. Enzalutamide plus standard hormone therapy can help many men with metastatic prostate cancer live longer. And that is news worth knowing.